Clinical Trial Update: Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

View source ↗

Summary

A clinical trial evaluating how body weight affects the pharmacokinetics of doxorubicin and cyclophosphamide in breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Breast Cancer | Status: WITHDRAWN